Vera Therapeutics CEO Sells Over 22,000 Shares

Marshall Fordyce cashes out a portion of his stake in the biotech company.

Apr. 16, 2026 at 9:33am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate pharmaceutical manufacturing equipment, conveying the technical sophistication and industrial scale of the biotech sector.An insider stock sale by Vera Therapeutics' CEO provides a glimpse into the complex machinery powering the biotech industry.Cambridge Today

Vera Therapeutics CEO Marshall Fordyce sold 22,951 shares of the company's stock on April 14th, 2026. The shares were sold at an average price of $44.05, resulting in a total transaction value of over $1 million. Following the sale, Fordyce still directly owns 235,244 shares of Vera Therapeutics, valued at $10.3 million.

Why it matters

Insider stock sales can provide insight into executive confidence and the overall health of a company. While Fordyce's sale represents a decrease of nearly 9% in his direct ownership, the transaction was made under a pre-arranged trading plan, suggesting it may have been part of a planned diversification strategy rather than a reaction to any specific concerns.

The details

The stock sale was executed under a Rule 10b5-1 trading plan, which allows corporate insiders to schedule stock transactions in advance and avoid allegations of insider trading. Vera Therapeutics is a clinical-stage biotech focused on developing novel immunotherapies for autoimmune and inflammatory diseases.

  • The stock sale occurred on Tuesday, April 14th, 2026.

The players

Marshall Fordyce

The CEO of Vera Therapeutics, Inc.

Vera Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing novel immunotherapies for autoimmune and inflammatory diseases.

Got photos? Submit your photos here. ›

The takeaway

While the CEO's stock sale represents a notable reduction in his direct ownership, the planned nature of the transaction suggests it was likely part of a broader portfolio management strategy rather than a reflection of any specific concerns about Vera Therapeutics' outlook.